Vicore Pharma: interesting play in the IPF space
On the back of its SEK882m capital increase and the start of a phase 2b trial with its lead asset buloxibutid in IPF, we take the opportunity to refresh our investment case on Vicore Pharma. Going into the phase 2b, we appreciate the diverse multi-modal MoA that buloxibutid presents which are relevVicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.